## Aishwarya Ravindran

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9337598/publications.pdf

Version: 2024-02-01

567281 72 1,468 15 citations h-index papers

36 g-index 73 73 73 1362 docs citations times ranked citing authors all docs

345221

#	Article	IF	CITATIONS
1	Neural epidermal growth factor-like 1 proteinÂ(NELL-1) associated membranous nephropathy. Kidney International, 2020, 97, 163-174.	5.2	213
2	Exostosin 1/Exostosin 2–Associated Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2019, 30, 1123-1136.	6.1	198
3	Semaphorin 3B–associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney International, 2020, 98, 1253-1264.	5.2	138
4	The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. Mayo Clinic Proceedings, 2019, 94, 2054-2071.	3.0	116
5	Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. Haematologica, 2020, 105, 348-357.	3.5	105
6	C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic. Mayo Clinic Proceedings, 2018, 93, 991-1008.	3.0	82
7	Thrombotic microangiopathy associated with monoclonal gammopathy. Kidney International, 2017, 91, 691-698.	5.2	78
8	C3 glomerulopathy associated with monoclonal IgÂis a distinct subtype. Kidney International, 2018, 94, 178-186.	5.2	77
9	In Patients with Membranous Lupus Nephritis, Exostosin-Positivity and Exostosin-Negativity Represent Two Different Phenotypes. Journal of the American Society of Nephrology: JASN, 2021, 32, 695-706.	6.1	56
10	Rosai-Dorfman Disease Displays a Unique Monocyte-Macrophage Phenotype Characterized by Expression of OCT2. American Journal of Surgical Pathology, 2021, 45, 35-44.	3.7	52
11	Proteomic Analysis of Complement Proteins in Membranous Nephropathy. Kidney International Reports, 2020, 5, 618-626.	0.8	51
12	Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. Nephrology Dialysis Transplantation, 2019, 34, 1508-1517.	0.7	46
13	Efficacy of BRAF-Inhibitor Therapy in <i>BRAF V600E</i> -Mutated Adult Langerhans Cell Histiocytosis. Oncologist, 2020, 25, 1001-1004.	3.7	25
14	Singleâ€agent cladribine as an effective frontâ€line therapy for adults with Langerhans cell histiocytosis. American Journal of Hematology, 2021, 96, E146-E150.	4.1	21
15	Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma. American Journal of Surgical Pathology, 2021, 45, 550-557.	3.7	20
16	Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival. American Journal of Hematology, 2021, 96, 1604-1610.	4.1	18
17	C3 glomerulonephritis with a severe crescentic phenotype. Pediatric Nephrology, 2017, 32, 1625-1633.	1.7	15
18	The significance of genetic mutations and their prognostic impact on patients with incidental finding of isolated del(20q) in bone marrow without morphologic evidence of a myeloid neoplasm. Blood Cancer Journal, 2020, 10, 7.	6.2	14

#	Article	IF	CITATIONS
19	Concomitant Erdheimâ€Chester disease and chronic myelomonocytic leukaemia: genomic insights into a common clonal origin. British Journal of Haematology, 2019, 187, e51-e54.	2.5	13
20	Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms. Haematologica, 2020, 105, e84-e86.	3 <b>.</b> 5	12
21	Pseudo-monoclonal gammopathy: a report of four cases. Haematologica, 2017, 102, e466-e469.	3.5	11
22	Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. Blood, 2021, 137, 513-523.	1.4	9
23	Sustained, complete response to pexidartinib in a patient with <scp><i>CSF1R</i></scp> â€mutated Erdheim–Chester disease. American Journal of Hematology, 2022, 97, 293-302.	4.1	9
24	Polyclonal Localized Light Chain Amyloidosis—AÂDistinct Entity?. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 588-592.	0.4	7
25	Karyomegalic interstitial nephritis in a renal allograft. American Journal of Transplantation, 2019, 19, 285-290.	4.7	7
26	Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic. Mayo Clinic Proceedings, 2020, 95, 944-954.	3.0	7
27	Standardized reporting of monoclonal immunoglobulin–associated renal diseases: recommendations from a Mayo Clinic/Renal Pathology Society Working Group. Kidney International, 2020, 98, 310-313.	5 <b>.</b> 2	7
28	Clinical and therapeutic implications of BRAF fusions in histiocytic disorders. Blood Cancer Journal, 2022, 12, .	6.2	7
29	Estimating the annual volume of hematologic cancer cases per hematologist–oncologist in the United States: are we treating rare cancers too rarely?. Leukemia and Lymphoma, 2017, 58, 251-252.	1.3	6
30	Florid dermatopathic lymphadenopathy-A morphological mimic of Langerhans cell histiocytosis. Clinical Case Reports (discontinued), 2018, 6, 1637-1638.	0.5	6
31	Etiologies of Extreme Thrombocytosis: A Contemporary Series. Mayo Clinic Proceedings, 2019, 94, 1542-1550.	3.0	6
32	<i>Desiderosmia</i> (olfactory craving): A novel symptom associated with iron deficiency anemia. American Journal of Hematology, 2017, 92, E93-E94.	4.1	5
33	High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia. American Journal of Hematology, 2017, 92, E164-E166.	4.1	5
34	A followâ€up on desiderosmia (olfactory craving), a novel symptom associated with iron deficiency anemia. American Journal of Hematology, 2017, 92, E546.	4.1	5
35	BK nephropathy with glomerular involvement. Kidney International, 2018, 94, 432.	5 <b>.</b> 2	4
36	Mimics of Erdheim–Chester disease. British Journal of Haematology, 2021, , .	2.5	3

3

#	Article	IF	Citations
37	Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience. Oncologist, 2022, 27, 144-148.	3.7	3
38	Clinical features and outcomes of non-pulmonary unifocal adult Langerhans cell histiocytosis. Blood Cancer Journal, 2022, 12, .	6.2	3
39	Patterns and utility of vitamin B12 and folate testing in patients with isolated thrombocytopenia. Annals of Hematology, 2019, 98, 1993-1994.	1.8	2
40	Hapticophagia: Tactile chew cravings in iron deficiency anemia. American Journal of Hematology, 2020, 95, E107-E108.	4.1	2
41	Aberrant expression of lymphoid enhancer–binding factor 1 in Hodgkin lymphoma. Human Pathology, 2022, 125, 2-10.	2.0	2
42	Characteristics and Outcome of Direct Antiglobulin Test-Negative Hemolytic Anemia: A Case Series. Blood, 2016, 128, 2451-2451.	1.4	1
43	BRAF Fusions in Histiocytic Disorders: Frequency and Clinical Characteristics. Blood, 2021, 138, 2582-2582.	1.4	1
44	Serologic Findings and Disease Associations among Adult Patients with Autoimmune Hemolytic Anemia: A Contemporary Series from a Large Tertiary Care Center. American Journal of Clinical Pathology, 2016, 146, .	0.7	0
45	Utility of Peripheral Smear and Bone Marrow Biopsy in the Workup of Thrombocytopenia: A Case Series. American Journal of Clinical Pathology, 2016, 146, .	0.7	0
46	High Prevalence of Monoclonal Gammopathy among Patients with Warm Autoimmune Hemolytic Anemia. American Journal of Clinical Pathology, 2016, 146, .	0.7	0
47	The Authors Reply. Kidney International, 2017, 92, 517.	5.2	0
48	Genetic Abnormalities in Complement Regulating Proteins in C3 Glomerulopathy. American Journal of Clinical Pathology, 2018, 150, S131-S131.	0.7	0
49	Evaluation of thrombocytopenia in the hematology clinic: a case series from a large tertiary care center. Blood Research, 2018, 53, 166.	1.3	0
50	The authors reply. Kidney International, 2018, 94, 632-633.	5.2	0
51	The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma. Haematologica, 2021, 106, 2261-2264.	3.5	0
52	Phenotypes and prognostic factors in adults with Langerhans cell histiocytosis Journal of Clinical Oncology, 2021, 39, 7049-7049.	1.6	0
53	<i>BRAF</i> <sup>V600E</sup> frequency and impact on outcomes in adults with langerhans cell histiocytosis Journal of Clinical Oncology, 2021, 39, 7050-7050.	1.6	0
54	Metastatic Thyroid Carcinoma in Bone. Mayo Clinic Proceedings, 2021, 96, 1670-1671.	3.0	0

#	Article	IF	CITATIONS
55	Dual Primary IGH Translocations in Multiple Myeloma: A Novel Finding. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e710-e713.	0.4	O
56	Estimating the Annual Volume of Hematologic Cancer Cases per Hematologist-Oncologist in the United States: Are We Treating Rare Cancers Too Rarely?. Blood, 2015, 126, 3297-3297.	1.4	0
57	Prevalence and survival of smoldering multiple myeloma in the US: Analysis using a national dataset Journal of Clinical Oncology, 2016, 34, 8035-8035.	1.6	0
58	Desiderosmia (Craving of Olfaction): A Novel Symptom Associated with Iron Deficiency Anemia. Blood, 2016, 128, 4827-4827.	1.4	0
59	Significant Variability in the Initial Workup of Thrombocytopenia in the Hematology Clinic - What Is the "Optimal" Workup?. Blood, 2016, 128, 5966-5966.	1.4	0
60	Clinical and Serological Characteristics of Cold Autoimmune Hemolytic Anemia with Concomitant Cold Agglutinin and Donath-Landsteiner Antibodies. Blood, 2017, 130, 927-927.	1.4	0
61	Frequency of Acquired Genetic Mutations and Their Prognostic Impact on Patients with Incidental Finding of Isolated 20q- in Bone Marrow without Morphologic Evidence of a Myeloid Neoplasm. Blood, 2018, 132, 4382-4382.	1.4	0
62	Monoclonal Gammopathy of Undetermined Significance (MGUS): Indications for Pre-Diagnostic Testing, Subsequent Diagnoses, and Follow-up Practice. Blood, 2018, 132, 2224-2224.	1.4	0
63	Desideromastica: Tactile Chew Cravings in Iron Deficiency Anemia. Blood, 2019, 134, 4815-4815.	1.4	0
64	Classical and Non-Classical Phenotypes of Erdheim-Chester Disease: Correlating Clinical, Radiographic, and Genotypic Findings. Blood, 2021, 138, 2566-2566.	1.4	0
65	Histopathologic Characterization of Vexas Syndrome. Blood, 2021, 138, 4656-4656.	1.4	0
66	Detection of Monoclonal Immunoglobulin By Mass Spectrometry in Patients Evaluated for Thrombotic Microangiopathy (TMA). Blood, 2020, 136, 17-17.	1.4	0
67	The Role of Staging Evaluation at Initial Diagnosis of Adult Patients with Clinically Isolated Pulmonary Langerhans Cell Histiocytosis. Blood, 2020, 136, 45-45.	1.4	0
68	Salicylates Potentiate and Broaden CRM1 Inhibitor Anti-Tumor Activity Via S-Phase Arrest and Impaired DNA-Damage Repair. Blood, 2020, 136, 17-18.	1.4	0
69	The Expression of Chromosome Region Maintenance Protein 1 (CRM1) in Large Cell Lymphoma. Blood, 2020, 136, 39-40.	1.4	0
70	Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and <i>DUSP22</i> rearrangements in Anaplastic Large Cell Lymphoma. Blood, 2020, 136, 22-23.	1.4	0
71	Histiocyte-rich pseudotumor — a post-chemotherapy radiologic dilemma. Journal of Hematopathology, 2022, 15, 45.	0.4	0
72	Thinking Beyond the Marrow: Deceptive Presentation of a Rare Malignant Neoplasm. Mayo Clinic Proceedings, 2022, 97, 1337-1338.	3.0	0